A less invasive method of reducing the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: Intravenous diclofenac sodium versus placebo

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study is to reduce the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by the administration of intravenous (IV) diclofenac sodium. Methods: This is a prospective, randomized, double-blinded control study. This study was performed in the hepatobiliary unit of general surgery department in University Kebangsaan Malaysia Medical Centre (UKMMC) from May 2015 to May 2016. A total of 128 patients were enrolled in this study. 59 patients were randomized into the treatment arm, while 63 were randomized into the control group. Patients were randomized by envelope system, and patients in the treatment arm received 75 mg of diclofenac sodium intravenously, within 30 min of ERCP commencement. Both groups were observed for PEP post-ERCP and their pain score recorded. Patients’ demographic data were also observed. Results: A total of 122 patients were included in the study, with 59 patients randomized into the treatment arm and 63 into the placebo arm. There was an increase of 7.6% PEP rates in the placebo group (12.7% vs. 5.1% in the treatment arm). However, this was not statistically significant (p=0.142) Conclusion: This study shows that IV diclofenac sodium can decrease PEP but is not statistically significant.

Original languageEnglish
Pages (from-to)140-144
Number of pages5
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume11
Issue number10
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint

Diclofenac
Endoscopic Retrograde Cholangiopancreatography
Pancreatitis
Placebos
Incidence
Malaysia
Therapeutics
Intravenous Administration
Demography
Pain
Control Groups
Peptamen

Keywords

  • Anti-inflammatory agents
  • Cholangiopancreatography
  • Endoscopic retrograde
  • Nonsteroidal
  • Pain
  • Prospective studies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{ae918c9c855f486199d155b5cd3a4c61,
title = "A less invasive method of reducing the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: Intravenous diclofenac sodium versus placebo",
abstract = "Objective: The purpose of this study is to reduce the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by the administration of intravenous (IV) diclofenac sodium. Methods: This is a prospective, randomized, double-blinded control study. This study was performed in the hepatobiliary unit of general surgery department in University Kebangsaan Malaysia Medical Centre (UKMMC) from May 2015 to May 2016. A total of 128 patients were enrolled in this study. 59 patients were randomized into the treatment arm, while 63 were randomized into the control group. Patients were randomized by envelope system, and patients in the treatment arm received 75 mg of diclofenac sodium intravenously, within 30 min of ERCP commencement. Both groups were observed for PEP post-ERCP and their pain score recorded. Patients’ demographic data were also observed. Results: A total of 122 patients were included in the study, with 59 patients randomized into the treatment arm and 63 into the placebo arm. There was an increase of 7.6{\%} PEP rates in the placebo group (12.7{\%} vs. 5.1{\%} in the treatment arm). However, this was not statistically significant (p=0.142) Conclusion: This study shows that IV diclofenac sodium can decrease PEP but is not statistically significant.",
keywords = "Anti-inflammatory agents, Cholangiopancreatography, Endoscopic retrograde, Nonsteroidal, Pain, Prospective studies",
author = "Chik, {I. A.N.} and Razman Jarmin and Affirul Ariffin and Othman, {Hairol Azrin} and Zamri Zuhdi and Azlanudin Azman and {Nik Mahmood}, {Nik Ritza Kosai}",
year = "2018",
month = "10",
day = "1",
doi = "10.22159/ajpcr.2018.v11i10.26474",
language = "English",
volume = "11",
pages = "140--144",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Asian Journal of Pharmaceutical and Clinical Research",
number = "10",

}

TY - JOUR

T1 - A less invasive method of reducing the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis

T2 - Intravenous diclofenac sodium versus placebo

AU - Chik, I. A.N.

AU - Jarmin, Razman

AU - Ariffin, Affirul

AU - Othman, Hairol Azrin

AU - Zuhdi, Zamri

AU - Azman, Azlanudin

AU - Nik Mahmood, Nik Ritza Kosai

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Objective: The purpose of this study is to reduce the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by the administration of intravenous (IV) diclofenac sodium. Methods: This is a prospective, randomized, double-blinded control study. This study was performed in the hepatobiliary unit of general surgery department in University Kebangsaan Malaysia Medical Centre (UKMMC) from May 2015 to May 2016. A total of 128 patients were enrolled in this study. 59 patients were randomized into the treatment arm, while 63 were randomized into the control group. Patients were randomized by envelope system, and patients in the treatment arm received 75 mg of diclofenac sodium intravenously, within 30 min of ERCP commencement. Both groups were observed for PEP post-ERCP and their pain score recorded. Patients’ demographic data were also observed. Results: A total of 122 patients were included in the study, with 59 patients randomized into the treatment arm and 63 into the placebo arm. There was an increase of 7.6% PEP rates in the placebo group (12.7% vs. 5.1% in the treatment arm). However, this was not statistically significant (p=0.142) Conclusion: This study shows that IV diclofenac sodium can decrease PEP but is not statistically significant.

AB - Objective: The purpose of this study is to reduce the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by the administration of intravenous (IV) diclofenac sodium. Methods: This is a prospective, randomized, double-blinded control study. This study was performed in the hepatobiliary unit of general surgery department in University Kebangsaan Malaysia Medical Centre (UKMMC) from May 2015 to May 2016. A total of 128 patients were enrolled in this study. 59 patients were randomized into the treatment arm, while 63 were randomized into the control group. Patients were randomized by envelope system, and patients in the treatment arm received 75 mg of diclofenac sodium intravenously, within 30 min of ERCP commencement. Both groups were observed for PEP post-ERCP and their pain score recorded. Patients’ demographic data were also observed. Results: A total of 122 patients were included in the study, with 59 patients randomized into the treatment arm and 63 into the placebo arm. There was an increase of 7.6% PEP rates in the placebo group (12.7% vs. 5.1% in the treatment arm). However, this was not statistically significant (p=0.142) Conclusion: This study shows that IV diclofenac sodium can decrease PEP but is not statistically significant.

KW - Anti-inflammatory agents

KW - Cholangiopancreatography

KW - Endoscopic retrograde

KW - Nonsteroidal

KW - Pain

KW - Prospective studies

UR - http://www.scopus.com/inward/record.url?scp=85054595577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054595577&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2018.v11i10.26474

DO - 10.22159/ajpcr.2018.v11i10.26474

M3 - Article

AN - SCOPUS:85054595577

VL - 11

SP - 140

EP - 144

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 10

ER -